Abstract. Cytotoxic T-lymphocyte activation and extension of the cell life span is necessary in order to enable immunotherapy to perform effectively against cancer. In the present study, mucin 1 (MUC1)-stimulated human mononuclear cells (M1SHMCs) were costimulated with bead-attached monoclonal antibodies specific for cluster of differentiation (CD)3 and CD28 receptors. The study was undertaken to determine whether costimulation was capable of enhancing the killing of cancer cells in vitro and of protecting non-obese diabetic severe combined immunodeficient mice from tumor development. Lysis of MCF-7 tumor cells by M1SHMCs was reduced following costimulation with anti-CD3 and anti-CD28. Furthermore, costimulation with anti-CD3 and anti-CD28 eliminated the protective effects of M1SHMCs on MCF-7 breast cancer cell growth in the non-obese diabetic severe combined immunodeficient mice. The present study suggested that costimulation with anti-CD3 and anti-CD28 is not advisable following antigen activation of lymphocytes under the conditions used here. Using a lower anti-CD3/CD28 bead to T-cell ratio may prevent immune suppression, however, further studies are required to support this hypothesis.
Introduction
Cytotoxic T-lymphocyte (CTL) activation and extension of the cell life span are necessary in order to enable immunotherapy to perform effectively against cancer cells (1) . CTLs are activated via the T-cell receptor (TCR; signal one) (2) , which induces the proliferation of CTLs. Engagement of a second receptor, cluster of differentiation 28 (CD28; signal two), by ligands on antigen-presenting cells, is required to prevent anergy and the apoptosis of CTLs (3) . This results in extension of the CTL lifespan. CTLs may be activated via the CD3 receptor [a component of the TCR (2) ] and the CD28 receptor using monoclonal antibodies specific for their respective receptors (4) . In order to obtain an adequate number of CTLs for the effective performance of immunotherapy, costimulation with anti-CD3 and anti-CD28 has been utilized (5) . Costimulated lymphocytes cells have been demonstrated to exhibit logarithmic growth and inhibit apoptosis via enhanced cytotoxicity for the targeting of tumor cells (6) . The present study aimed to determine whether the mucin 1 (MUC1)-stimulated human mononuclear cells (M1SHMCs) of breast cancer patients would demonstrate expanded levels of growth without compromising their ability to kill cancer cells when costimulated with anti-CD3 and anti-CD28.
Materials and methods

MUC1-variable number tandem repeat 1 (VNTR1) peptide.
GSTAPPAHGVTSAPDTRPAP (7) peptide was synthesized by American Peptide Co., Inc., (Sunnyvale, CA, USA) and Novartis International AG (Basel, Switzerland).
Anti-CD3/CD28 antibody beads. Anti-CD28 antibodies were obtained from Murine Hybridoma 9.3 (8), which was a gift from Professor John Hansen (University of Washington, Seattle, USA). Dynabeads ® M-450 Tosylactivated (Thermo Fisher Scientific, Inc., Waltham, MA, USA) are superparamagnetic polystyrene beads, which were activated using p-toluenesulfonyl chloride, according to the manufacturer's instructions. Anti-CD3 (OKT3; Beckman Coulter, Inc., Brea, CA, USA) and anti-CD28 (5 µg each) were subsequently added to a centrifuge tube containing Buffer B Dynabeads kit solution. The tube was then placed in a Dynabeads ® Rotator Mixer (Thermo Fisher Scientific, Inc.) and incubated for 24 h at 37˚C with 5% CO 2 . The following day, the tube was placed into the Cell culture conditions. Procedures were performed as previously described (9) . Mononuclear cells were not human leukocyte antigen typed, as our previous studies (10) (11) (12) and another literature study (13) identified that cytotoxicity by M1SHMC may be non-major histocompatibility complex-restricted. The cells were cultured at 2x10 6 cells/ml in AIM V ® serum-free lymphocyte medium (Gibco; Thermo Fisher Scientific, Inc.) and maintained in a 37˚C humidified 5% CO 2 atmosphere (14). Interleukin-2 (100 IU/ml; Novartis International AG) was added twice/week. The cells were stimulated with MUC1-VNTR1 peptide on days zero and seven, at 1 µg/ml. The cells were harvested on day eight.
Costimulation of mononuclear cells. M1SHMCs (2.0x10
7 cells) were costimulated by anti-CD3/anti-CD28 beads according to the manufacturer's instructions, at a 3:1 ratio of beads to cells (6) in AIM V ® medium. This occurred at the intervals shown in Fig. 1 (once, twice or three times/week) or three times/week, as shown in Figs. 2-4 (days 9, 11 and 13, with harvesting on day 14).
Growth of MCF-7 cell line.
Human breast carcinoma MCF-7 cells were utilized as the target cells (15) . The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 1% bovine insulin (Gibco Life Technologies) and 1% L-glutamine (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C with 5% CO 2 . Medium was replaced twice/week by removal of the DMEM and addition of 15 ml fresh DMEM to the flask.
Chromium release assays. The MCF-7 cells were used as targets in a Chromium 51 release assay (16 Cr release control wells. The maximum target control wells had 2% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) added in place of the effector cells, in order to lyse the target cells. Assays were incubated for 18 h, which has been identified to be superior to 4 h (9), at 37˚C with 5% CO 2 , and each assay was performed in triplicate. Plates were centrifuged at 200 x g, and one half of the 100 µl supernatant was harvested. Radioactivity released into the supernatant was measured using liquid scintillation or γ counting. The specific percentage lysis was calculated using the formula below, where cpm represents counts/minute:
In vivo protection experiment. Animal care was in accordance with the guidelines of Texas Tech University Health Sciences Center (Amarillo, TX USA). Mice were housed in individually ventilated cages supplied HEPA filtered air, with a maximum of five mice per cage. Each animal holding room was supplied with 10-15 air changes per hour, and pressurized relative to the immunocompetance of the animals. The light/dark cycle was set from 07:00-19:00 (light cycle-low intensity). Diet and water was ad libitum, and the water was de-ionized and autoclaved. The immunodeficient diet was Global Irradiated Code 2918 (Harlan Teklad Labs, Houston, TX USA). Mice were housed at a temperature of 68-79˚F and humidity between 30-70%. Female non-obese diabetic severe combined immunodeficient mice (Jackson Laboratory, Bar Harbor, ME, USA), at 6-12 weeks of age, were injected subcutaneously (SC) (mean experimental cpm -mean spontaneous cpm) % lysis (mean maximum cpm -mean spontaneous cpm)   in the back of the neck, with 0. 
Results
Growth of peripheral blood mononuclear cells with anti-CD3/anti-CD28 costimulation.
Monoclonal antibodies were bound onto beads in order to costimulate patient lymphocytes. Cells underwent costimulation by anti-CD28/anti-CD3 M1SHMC were then costimulated with anti-CD3/anti-CD28 beads on days 9, 11 and 13, and harvested on day 14. Female non-obese diabetic severe combined immunodeficient mice were injected SC with 5x10 6 MCF-7 tumor cells in the right posterior neck (on day 0). An estrogen pellet was injected SC at the same time, but at an alternative site to the tumor cells, to allow tumor growth. On the same day that tumor cells were injected IP, control animals were injected with phosphate-buffered saline or the anti-CD3/CD28 antibody beads individually. The first group of 7 mice received MCF-7; the second group of 1 mouse received anti-CD3/CD28 antibody beads IP; the third group of 4 mice received 5x10 7 M1SHMC IP; and the fourth group of 4 mice received M1SHMC and anti-CD3/CD28 antibody beads. Each mouse was examined for tumor development three times/week for one month. The observed tumor development at 28 days post-injection was used for statistical analysis. Data are expressed as the mean ± standard error P=0.4 (Chi-square) group 3 vs. group 4. Certain bars are masked by the symbols. The Y axis is the fraction of the number of mice with tumors divided by the total number of mice injected. CD, cluster of differentiation; M1SHMC, mucin 1 stimulated human mononuclear cells; SC, subcutaneously; IP, intraperitoneally.
Dynabeads one, two or three times/week. Cells costimulated three times/week demonstrated optimal proliferation and an increased cell count, from 10 to 68 million (Fig. 1) . Costimulation once or twice/week did not significantly increase the cell number. Each bar represents a single culture, thus no statistical analysis was performed. Thus, M1SHMC were costimulated three times with anti-CD3/anti-CD28 beads on days 9, 11 and 13, and harvested on day 14.
Specific lysis of MCF-7 cells by M1SHMCs was compared to
M1SHMCs costimulated with anti-CD3/anti-CD28 beads at the indicated effector to target ratio. M1SHMCs were then compared with costimulated M1SHMCs using an in vitro MCF-7 cell-killing assay and in an in vivo MCF-7 tumor formation inhibition experiment. Costimulation of M1SHMC with anti-CD3/anti-CD28 beads did not result in enhanced killing of the MCF-7 cells. Reduced killing of MCF-7 cells was observed in two separate experiments (Figs. 2 and 3 ). In the first experiment, at a 10:1 ratio of effector to target cells, the M1SHMCs possessed a specific lysis rate of 67±3% vs. 27±6% (P=0.004, two-tailed t test) for the anti-CD3/anti-CD28 bead costimulated M1SHMCs (Fig. 2) . In the second experiment, the observed difference was even greater. At a 10:1 ratio of effector to target cells, the M1SHMCs possessed a specific lysis rate of 99±3% vs. 14±0% + 0 (P<0.0001, two-tailed t test) for the anti-CD3/anti-CD28 bead costimulated M1SHMC (Fig. 3) .
Effect of costimulation with anti-CD3/anti-CD28 on the inhibition of tumor production by M1SHMCs.
The in vivo results were consistent with those observed in vitro. There was enhanced tumor formation in the animals injected with breast cancer patients PBMCs, costimulated with anti-CD3 and anti-CD28 beads with or without MUC1 stimulation (Fig. 4) . In the first group of 7 mice that received MCF-7, 4 developed tumors (57%); in the second group of 1 mouse that received anti-CD3/CD28 antibody beads, a tumor developed (100%); in the third group of 4 mice that received M1SHMC, two mice developed tumors (50%); and in the fourth group of 4 mice that received M1SHMC and anti-CD3/CD28 antibody beads, all mice developed tumors (100%; P=0.4 using Chi-square, group 3 vs. group 4).
Discussion
This present study was performed in order to investigate the optimum interval of time for the costimulation of M1SHMCs with anti-CD3/CD28 antibody beads, to promote the proliferation of CTLs and the killing of breast cancer cells, thereby preventing tumor growth. With regard to lymphocyte cell growth, the most frequent intervals of costimulation with anti-CD3/CD28 antibody beads provided the optimal rate of cell proliferation. However, the anti-CD3/CD28 bead costimulation of M1SHMCs resulted in a significant decrease in breast cancer cell killing activity. This led to enhanced tumor cell growth. Whilst costimulation with anti-CD3/CD28 antibody beads may be utilized for the activation of lymphocytes (17), the results of the present study suggested that costimulated M1SHMCs, whilst exhibiting higher rates of proliferation, possess a reduced ability to kill cancer cells, and thus this method of treatment may not be advisable following antigen activation of lymphocytes under the conditions used here. We have previously shown that continued stimulation of CTL rendered them anergic (9) . In support of this, constitutive proliferating CAR T cells showed inferior antitumor effect (18). In addition, repetitive signaling rendered CAR T cells susceptible to activation -induced cell death (AICD) (19) .
In conclusion, whilst CTL activation and extension of the cell life span may be necessary in order to enable immunotherapy to perform effectively against cancer cells (1), excessive proliferation and signaling of the T cells may inhibit their antitumor activity. This resulting immune suppression may be prevented by using a lower anti-CD3/CD28 bead: T-cell ratio (20) , which should reduce the T cells signaling through the CD3 complex, and reduce activation -induced cell death. Another alternative is altering the anti-CD3/CD28 ratios (21) , where a lower anti-CD3/CD28 ratio should reduce activation -induced cell death and reduce apoptosis through CD28 engagement. A more physiological method that could be utilized for costimulation may be artificial antigen-presenting cells (22, 23) , with the addition of additional costimulatory and pro-survival molecules.
